WF11899A, B and C are novel echinocandin type of lipopeptide antibiotics produced by Coleophoma empetri F-1 1 8991}. These compoundswere structurally characterized by having a sulfate moiety. Although the other related natural lipopeptides lacked water-solubility, WF11899A possessed excellent watersolubility ascribed to the sulfate moiety.
Echinocandin B and aculeacin A, which are representative of natural antifungal lipopeptides, are well known as l,3-/?-glucan synthesis inhibitors2~4). The glucan exists in fungal cell wall, not in mammalian cells. It is, therefore, expected to be a suitable target for antifungal agents. These antibiotics indeed showed an excellent anti-Candida activity by disturbing fungal cell wall biosynthesis, but they had hemolytic potential5*. Semi-synthetic cilofungin6), an echinocandin B derivative having a 4-octyloxybenzoyl side chain, showed the possibility that the hemolytic toxicity can be reduced.
In this paper, WF11899A, B and C were compared with the related lipopeptides for in vitro and in vivo antifungal activity, inhibitory activity on l,3-/?-glucan synthesis and hemolytic activity.
Materials and Methods

Compounds
AculeacinA was a generous gift of Toyo Jozo Co., Ltd., Tokyo, Japan. Echinocandin B was isolated from the cultural broth of Aspergillus nidulans var. roseus A42355 NRRL-1 1440. Cilofungin was generously provided by Eli Lilly and Company, Indianapolis, Indiana, U.S.A., and further, the compound was semi-synthesized in our laboratory from echinocandin B according to the method described by Debono et al.7) Amphotericin B was obtained from Sigma. Fluconazole was synthesized in the NewDrug Research Laboratories of Fujisawa Pharmaceutical Co., Ltd., Osaka, Japan.
In Vitro Antifungal Activity Microbroth dilution assay: Each inoculum was prepared as followed. The Candida cultures were incubated in yeast-maltose (YM) broth for 20 hours at 37°C at the standing condition. The culture of Cryptococcus neoformans was grown in YMbroth for 20 hours at 30°C with shaking. The cell suspension VOL.47 NO. 10 THE JOURNAL OF ANTIBIOTICS 1093 was prepared by washing the cultured cells with sterile saline. The filamentous fungi (Aspergillus spp.) were cultured on the YMagar slants for seven days. The spores were harvested in sterile saline, and filtered through gauze. Finally, the fungal cells or spores were resuspended in yeast nitrogen base (YNB) containing 0.5% glucose for inoculation.
Antifungal activity was measured in YNBcontaining 0.5% glucose by microbroth dilution assay using 96-well microtiter plates. The compounds were dissolved in methanol, and diluted serially two-fold with YNBin microplates. The test microorganisms were inoculated to each well to yield 1 x 104cfu/well in 100 fA. The plates were incubated for 22 hours at 37°C (Candida spp. and Aspergillus spp.) or 48 hours at 30°C (C. neoformans). IC50 was determined by measuring turbidity at 600 nm on microplate reader. Agar dilution assay: Compoundswere diluted two-fold in YNBagar containing 0.5% glucose, and their concentrations ranged from 10 to 0.08/zg/ml. The fungal cells or spores suspensions
(1 x 105~1 x 106cfu/ml) in sterile saline were inoculated on the surface of the prepared plate by stamp method. The plate was incubated for 36 hours at 37°C, and then the MICs were determined.
In Vivo Efficacy
The in vivo anti-Candida activity were evaluated in a mousemodelof systemic infection. C. albicans FP-633, a clinical isolate in Fujisawa culture collection, was used in this study. The inoculum was prepared from a three day old culture of YMagar slant. ICR mice (female, four weeks old) were intravenously injected with 2 x 106cells of the yeast. All compounds were solublized in 20%polyethylene glycol 400 saline, and administered subcutaneously one hour after challenge and once a day for three consecutive days.
Glucan Synthase Assay Enzyme (membrane fraction) preparations and assay procedures were conducted according to the method described by Sawistowska-Schroder et al.^with some modifications. C. albicans 6406 kindly supplied from Dr. D. Kerridge of University of Cambridge was used in this study. Briefly, the yeast cells were grown to logarithmic phase (absorbance at 660nm; 0.42) in YNBmedium supplemented with 2% glucose at 30°C under shaking. The cells were harvested by centrifugation, washed and suspended in ice-cold buffer A (50 mMTris-HCl buffer (pH 7.5), 1 mMEDTA, 1 mM/?-mercaptoethanol, 1 m sucrose and 25fiu GTP). The cells were broken by mixing with 0.4mmglass beads on a vortex mixer and the glass beads were washed with ice-cold buffer B (buffer A minus 1 m sucrose), and the cell debris was removed by centrifugation. The supernatant fluids were centrifuged at 100,000 x g for 45 minutes at 4°C. The pellet was washed by ultracentrifugation in buffer B, resuspended in buffer C (buffer B -glycerol, 2 : 1) at lOmg protein/ml and stored at -80°C as a source of enzyme.
Measurement of inhibitory activity on glucan synthase was carried out as follows. Twoand a half fA of test compound solution or vehicle was incubated with 25 jA of the reaction mixtures (50mMTris-HCl buffer (pH 8.0), 0.8% BSA, 0.1mM GTP, 0.1% CHAPS, 0.05% Tween 80 and the particulate enzyme (40 fig protein) ) for 15 minutes at room temperature. After the incubation, 25 /A of UDP-[C/-14C]glucose (0.35juCi/ml, 1 mM)was added to the reaction vessel to react for 60 minutes at room temperature. The reaction was terminated by the addition of 100 /d of ice-cold 5% trichloroacetic acid (TCA) and allowed to stand on the ice. The resultant precipitate was collected on a GF/Cglass filter and counted for radiolabel activity in toluene scintillator.
Hemolytic Activity Fresh red blood cells prepared from ICR mouse (female, four weeks old) were used in the hemolytic assay. The whole blood cells were collected under the heparinized condition, and washed with saline three times. The resultant red blood cells (RBC) were suspended with saline to yield 2% (v/v) suspension. Fifty /il of RBCsuspension was added to 50fA of the compoundsolution which were serially two-fold diluted with saline in U-bottom microtiter plates. The plate was incubated for two hours at room temperature with gentle shaking, and then allowed to stand for a while to sediment RBC.The hemolytic activity was determined by visual observation. The minimumlytic concentration (MLC)is defined as the lowest concentration of a compoundwhich lyse red blood cells8). OCT. 1994 Results and Discussion
In Vitro Antifungal Activity The in vitro antifungal activities of WF11899A,B and C were compared with that of aculeacin A using microbroth dilution method (Table 1) . These compounds showed a similar anti-yeast spectrum to aculeacin A, that is, highly active against Candida spp., but not active against Cryptococcus neoformans. WF11899A, B and C exhibited the almost same activity against Candida albicans, the IC5Os of them against four clinical isolates of C. albicans ranged from 0.004 to 0.03 jUg/ml. The IC5Os of aculeacin A was from 0.008 to 0.06/ig/ml. WF11899A, B and C appeared to be more active against the other three Candida spp. than aculeacin A, and were effective also against Aspergillus spp. Judging from microscopic observations, these compounds were fungicidal against Candida spp., but they were mildly fungistatic against filamentous fungi even at the highest concentration (5 /xg/ml), as well as aculeacin A. Echinocandin/aculeacin type of lipopeptides were reported to be antibiotics with narrow spectrum by agar dilution method. Therefore, we compared the MICs by agar dilution method with the IC5Os by microbroth dilution method. Table 2 shows the MICs and the IC5Os of WF11899A,echinocandin B, cilofungin and amphotericin B. The antifungal spectra of the structurally related lipopeptides, including WF11899A by agar dilution method, These determinations were measured in YNBcontaining 0.5% glucose. Tested compound was subcutaneously administered to ICR mice (n=8) infected with C. albicans FP633. a The day at which all non-treated infected mice died. were consistent with the results previously reported, which showed that the antifungal activity of the lipopeptides limited to Candida spp. The MICs of these lipopeptides against Aspergillus fumigatus and A. niger were > 10^g/ml. However, IC5Os (microbroth dilution method) of them were diversified and the range was from < 0.003 to 5 /zg/ml. By contrast, the IC5Os of amphotericin B was nearly identical with itsMICs.
In Vivo Activity The protective efficacy of WF11899A, B and C against murine systemic infection with C. albicans was examined (Fig. 1) . These compounds significantly prolonged the survival of infected mice. In particular, all mice treated with WF11899A at the dose of 3 mg/kg survived during the observations. The ED5Osof WF11899A, B and C at day 14 after challenge were 2.7, 4.6 and > lOmg/kg, respectively. In an additional experiment, the efficacy of WF11899A was compared with those of the other lipopeptides and an azole compound. As shown in Table 3 , the result demonstrate that WF11899A is superior to echinocandin B and cilofungin, and as active as fluconazole.
Inhibitory Activity on Glucan Synthase The mode of action of echinocandin analogs was reported to be inhibition of l,3-/?-glucan synthase. Inhibitory activity ofWF1 1899A, B, C and the related lipopeptides on incorporation of UDP-[14C]glucose into TCAinsoluble fractions were examined. The IC5Os of them were listed in Table 4 . WF11899A, B and C inhibited the glucan synthesis which was catalyzed by the particulate enzyme prepared from C. albicans 6406. The potency ofWF11899A and B seemed to be slightly higher than those of echinocandin B and cilofungin.
Hemolytic Activity The hemolytic activities of the lipopeptides and amphotericin B were tested using mouse red blood cells (Table 5 ). WF1 1899A, B and C were 8-fold less hemolytic than amphotericin B, but almost the same as aculeacin A and echinocandin B. Cilofungin, the derivative overcoming hemolysis of echinocandin B, was not hemolytic as previously reported by Lilly's researchers5).
Discussion
The in vitro and in vivo antifungal activities of WF11899A,B and C were evaluated and compared with those of other antifungal antibiotics. The results indicated that these compoundshad a potent anti-Cawdida activity. In particular, WF11899A showed the most efficacy on a murine model of systemic candidiasis. The spectrum of echinocandin analogs was considered to be limited in Candida spp., but the growth of Aspergillusfumigatus and A. niger was mildly suppressed by WF11899A,B and C as well as the other lipopeptide antibiotics at the much lower concentration than their MICsobtained by the conventional agar dilution method. The evaluation of cilofungin indicated that it had anti-^4. fumigatus activity on a systemic aspergillosis mouse model despite its high MIC9), and its efficacy was correlated with its inhibitory activity against l ,3-/?-glucan synthase prepared from A. fumigatus1 0). In our preliminary experiment, WF11899Aalso showed in vivo anti-A. fumigatus activity. These observations suggested that it was difficult to evaluate the effect of echinocandin analogs against filamentous fungi by conventional agar dilution method. The microbroth dilution method, by which we can observe mild growth inhibition, seems to be the alternative for the evaluation of echinocandin analogs.
WF11899A, B and C, as well as aculeacin A and echinocandin B, lysed mouse red blood cells in vitro. To decrease the hemolytic toxicity, echinocandin B was modified to cilofungin by enzymatic deacylation1 1} and chemical reacylation7). On the other hand, natural echinocandin analogs, pneumocandins, were reported to be nor or little hemolytic8'12). These compounds demonstrated that the antifungal activity was not linked to the hemolytic toxicity, and substitution of the side chain let this class of compounds proceed to further evaluations. The chemical modifications of WF11899A indeed reduced the hemolytic toxicity, keeping its good water-solubility and anti-Candida activity. These results will be published elsewhere.
